We used a set of biopsies from four patients with BRAFV600E-mutant melanoma, where for each patient, samples before and after vemurafenib (a clinical BRAF inhibitor) treatment, as well as matching normal references, are available. The gene discussed is BRAF; the disease is melanoma.